Intermittent tosstherapy of plasmacytoma with melphalan and predniso (lo) ne
Braun, H.J.
Minerva Medica 64(14): 679-682
1973
ISSN/ISBN: 0026-4806 PMID: 4575093 Document Number: 68760
Document emailed within 1 workday
Related Documents
Adler, A.; Keisari, Y.; Ofir, R. 1985: Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy Journal of the National Cancer Institute 74(2): 429-436Hall, A.G.; Matheson, E.; Hickson, I.D.; Foster, S.A.; Hogarth, L. 1994: Purification of an alpha class glutathione S-transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation Cancer Research 54(13): 3369-3372
Guida, M.; Casamassima, A.; Abbate, I.; Paradiso, A.; Zito, A.; Marzullo, F.; Lorusso, V.; Timurian, A.; Cramarossa, A.; De Lena, M. 1994: Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different nosological entities? Tumori 80(5): 370-377
Vistica, D.T.; Rabon, A.; Rabinovitz, M. 1979: Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marrow precursor cells (CFU-C) and murine L1210 leukemia cells Research Communications in Chemical Pathology and Pharmacology 23(1): 171-183
Follette, D.M.; Steed, D.L.; Foglia, R.; Fey, K.; Buckberg, G.D. 1978: Advantages of intermittent blood cardioplegia over intermittent ischemia during prolonged hypothermic aortic clamping Circulation 58(3 Part 2): I200-I209
Belasco, J.B.; Mitchell, C.D.; Rohrbaugh, T.; Rosenstock, J. 1987: IV melphalan in children Cancer Treatment Reports 71(12): 1277-1278
Lawrence, B.V. 1980: Anaphylaxis due to oral melphalan Cancer Treatment Reports 64(4-5): 731-732
Vistica, D.T.; Rabon, A.; Rabinovitz, M. 1978: Enhancement of melphalan therapy with glutaminase:asparaginase Research Communications in Chemical Pathology and Pharmacology 22(1): 83-92
Besses, C. 2001: 40 years ago in Medicina Clinica. The introduction of melphalan in Spain Medicina Clinica 117(1): 24-26
Takahashi, I.; Ohmoto, E.; Nakada, H.; Inagaki, N.; Nonaka, K.; Takeuchi, M.; Osada, K.; Tsurumi, N.; Uchida, K.; Yorimitsu, S. 1988: Clinical effects of K-18 (IgG-melphalan) in hypoplastic leukemia: a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(1): 159-162
Levin, M.; Chokas, W. 1987: Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone New England Journal of Medicine 317(18): 1155-1156
Alexanian, R.; Migliore, P.J. 1970: Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy Journal of Laboratory and Clinical Medicine 75(2): 225-233
Kroon, B.B.; Van Geel, A.N.; Benckhuijsen, C.; Wieberdink, J. 1987: Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs Anticancer Research 7(3 Part B): 441-442
Teicher, B.A.; Crawford, J.M.; Holden, S.A.; Cathcart, K.N. 1987: Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity Cancer Research 47(19): 5036-5041
de Castiglione, R.; Gozzini, L.; Galantino, M.; Corradi, F.; Arlandini, E.; Molinari, I.; Ciomei, M. 1991: Bombesin receptor antagonists. 3. Irreversible alkylating analogues: melphalan derivatives Farmaco 46(6): 743-757
Kergueris, M.F.; Milpied, N.; Moreau, P.; Harousseau, J.L.; Larousse, C. 1994: Pharmacokinetics of high-dose melphalan in adults: influence of renal function Anticancer Research 14(6a): 2379-2382
Medina, D. 1977: Enhancement of mammary tumor formation in mice by a cytostatic drug, melphalan Cancer Research 37(1): 317-319
Kvols, L.K.; Eagan, R.T.; Myers, R.P. 1977: Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report Cancer Treatment Reports 61(2): 311-312
Chłopkiewicz, B.; Anuszewska, E. 1989: Comparison of transforming, antimitotic and chromosomal aberration-inducing properties of melphalan and cyclophosphamide Polish Journal of Pharmacology and Pharmacy 41(4): 293-298
Miller, A.B.; Klaassen, D.J.; Boyes, D.A.; Dodds, D.J.; Gerulath, A.; Kirk, M.E.; Levitt, M.; Pearson, J.G.; Wall, C. 1980: Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer Canadian Medical Association Journal 123(5): 365-371